Cell Source, Inc. (OTCBB: CLCS) is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company’s patented "Veto-Cell" technology represents a major breakthrough in immune system management - safe and selective “tolerizing” of immune response. Cell Source’s technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific “desirable” foreign cells while continuing to attack all other potential threats. Cell Source is currently commercializing this groundbreaking innovation. Potential applications range from facilitating bone marrow and organ transplantation to effectively treating both blood cancers (e.g., Lymphoma) and non-malignant congenital diseases (e.g., Sickle Cell Anemia). SNNLive spoke with Itamar Shimrat, CEO of Cell Source, Inc. at the LD Micro "Main Event" 2014 in Bel Air, CA.
Mr. Shimrat begins with an overview of the company, “Cell Source is an area of biotechnology that is particularly hot right now – immunotherapy and regenerative medicine. The company is developing some proprietary cell therapies to use human cells to treat different ailments. We have three different areas in our activity and I’ll just go through them one at a time. First of all, for patients who need a bone marrow transplantation or a major organ transplant, they face a dual challenge of both finding a match donor and also overcoming transplantation rejection. We can address both those issues by facilitating transplants with ‘mismatched’ or only partially matched donors for both bone marrow and major organs, reducing the amount of immune suppression dramatically at the time of the transplant and eliminating, in the case of organ transplants, completely eliminating the need for immune suppression after the transplant which dramatically increases the quality of life for patients.”
He gives an update on Cell Source’s clinical pipeline, “Our first human clinical trials is slated to begin sometime within the next year in Europe, where we’re combining two existing treatments that are already in the clinic in a proprietary combination. Because these are already clinical treatments the timescales for getting them approved for trials and going through the trials and getting them approved to treat patients are relatively fast compared to completely preclinical treatments. We’re talking about doing what’s called the phase I/II study where you directly go to sick patients, so you’re demonstrating both safety and efficacy so it doesn’t harm and it does good. A phase I/II study can be completed within two to three years and in some cases for these type of treatments in these type of illnesses, after the phase I/II or after phase II study, you can already start treating a limited number of patients and have revenues and save lives even before you do a phase III.”
He goes on to discuss 2015, “First of all, for the treatment that I just talked about, which is the facilitating mismatched bone marrow transplantations, getting in the clinic and getting some good human data. For our veto cell technology, which I haven’t mentioned in this particular interview yet which has been in pre-clinical studies in animals extremely effective in treating Lymphoma and Leukemia, which are blood cancers, already finalizing the human treatment protocol for that and applying for approval or IND to begin the treatments for that product and various developments in other products of ours in terms of patent announcements, major publications and research moving forward.” For more information, check out their website: www.Cell-Source.com
© 2017 Stock News Now
Supported by Superior Web Solutions